472 related articles for article (PubMed ID: 24860154)
1. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.
van Heeswijk RP; Dannemann B; Hoetelmans RM
J Antimicrob Chemother; 2014 Sep; 69(9):2310-8. PubMed ID: 24860154
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
Pandie M; Wiesner L; McIlleron H; Hughes J; Siwendu S; Conradie F; Variava E; Maartens G
J Antimicrob Chemother; 2016 Apr; 71(4):1037-40. PubMed ID: 26747099
[TBL] [Abstract][Full Text] [Related]
3. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
4. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
[TBL] [Abstract][Full Text] [Related]
5. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
Svensson EM; Murray S; Karlsson MO; Dooley KE
J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
7. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
8. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
Gras J
Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939
[TBL] [Abstract][Full Text] [Related]
9. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
[TBL] [Abstract][Full Text] [Related]
10. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
[TBL] [Abstract][Full Text] [Related]
11. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
Maartens G; Brill MJE; Pandie M; Svensson EM
Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
[TBL] [Abstract][Full Text] [Related]
13. TMC207 becomes bedaquiline, a new anti-TB drug.
Palomino JC; Martin A
Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
[TBL] [Abstract][Full Text] [Related]
14. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
Kakkar AK; Dahiya N
Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
[TBL] [Abstract][Full Text] [Related]
15. Assessment of preclinical drug interactions of bedaquiline by a highly sensitive LC-ESI-MS/MS based bioanalytical method.
Kotwal P; Magotra A; Dogra A; Sharma S; Gour A; Bhatt S; Wazir P; Singh PP; Singh G; Nandi U
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1112():48-55. PubMed ID: 30851617
[TBL] [Abstract][Full Text] [Related]
16. Bedaquiline.
Goulooze SC; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
[No Abstract] [Full Text] [Related]
17. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
Nagabushan H; Roopadevi HS
J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373
[TBL] [Abstract][Full Text] [Related]
18. ▼Bedaquiline for multidrug-resistant tuberculosis.
Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
[TBL] [Abstract][Full Text] [Related]
19. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Svensson EM; Dooley KE; Karlsson MO
Antimicrob Agents Chemother; 2014 Nov; 58(11):6406-12. PubMed ID: 25114140
[TBL] [Abstract][Full Text] [Related]
20. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
